XML 68 R56.htm IDEA: XBRL DOCUMENT v3.19.1
Pro Forma Financial Statements (Details 5)
12 Months Ended
Dec. 31, 2018
USD ($)
Purchase consideration:  
Common stock $ 44,341,847 [1]
Estimated Fair Value of Assets Acquired:  
Cash and cash equivalents 636,666
Accounts receivable 43,204
Accounts receivable - related parties 147,848
Property and equipment 58,150
Security deposits 10,440
Total assets acquired 896,308
Estimated Fair Value of Liabilities Assumed:  
Due to shareholders
Accrued expenses and other current liabilities 83,026
Tenant security deposit 2,880
Total liabilities assumed 85,906
Total net assets acquired 810,402
Goodwill as a result of the Merger $ 43,531,445
[1] 29,561,231 shares of ABVC common stock to be issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, the closing share price of ABVC on February 5, 2019.